Trial Profile

A Time-window StratifiedRandomised, Open-label, Controlled, Multicentered Phase IIa Trial to Assess the Efficacy and Safety of Thrombolysis with Recombinant Human Prourokinase in the patients with Acute Acute Ischaemic Stroke

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Nov 2023 Primary endpoint [modified Rankin scale (mRS) score Group A (rhPro-UK 50 mg) vs Group B (rhPro-UK 35 mg) assessed 4.5h to 6h of AIS onset] has not been met as per results published in the CNS Drugs.
29 Nov 2023 Results (n= 80) of this trial evaluating therapeutic effects and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke (AIS) in the 4.5-6 h therapeutic time windows published in the CNS Drugs.
08 Feb 2019 Preliminary results presented at the International Stroke Conference 2019

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com